检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:王菊香[1] 朱新波[2] 曾炜炜[1] 钱江潮[1] 周海霞[1] 黄珍[1] 方希敏[1] 徐霞[1] 李原[1]
机构地区:[1]温州医学院附属育英儿童医院血液科 [2]温州医学院药理学教研室
出 处:《中国临床药理学与治疗学》2009年第9期1052-1055,共4页Chinese Journal of Clinical Pharmacology and Therapeutics
基 金:温州市科技局项目基金资助(Y20070116)
摘 要:目的:通过观察急性淋巴细胞白血病患儿应用柔红霉素(daunorubicin,DNR)化疗后其血浆N末端脑利钠肽原(N-terminal pro-brain natriureticpeptide,NT-pro BNP)水平的改变及应用左卡尼汀心肌保护药物后NT-pro BNP水平的变化,探讨能早期监测DNR心肌毒性并可筛选出更好保护心肌药物的指标。方法:选择2006-2008年新诊断的急性淋巴细胞白血病患儿22例,均采用长春新碱+柔红霉素+左旋门冬酰胺酶+泼尼松(VDLP)方案诱导化疗,化疗期间分别应用左卡尼汀口服液(Levocarnitine oral solution)(治疗组)或未予任何心肌保护药物(对照组)。在应用DNR前后用交体基免疫分析法测定患儿血浆NT-proBNP水平,并同时常规检测患儿化疗前后心肌肌钙蛋白I(cTnI)、心肌酶谱(LDH1、CPK-MB)及心电图(ECG)。结果:治疗组(L-CN组)患儿化疗后血浆NT-pro BNP浓度从(53±11)pg/mL增加到(162±27)pg/mL(P<0.01)。对照组从(51±10)pg/mL增加到(194±38)pg/mL(P<0.01)。两组化疗前NT-pro BNP水平差异无统计学意义(P>0.05),而化疗后治疗组(L-CN组)患儿血浆NT-pro BNP水平较对照组低(P<0.05),治疗组治疗后血浆NT-pro BNP的改善情况优于对照组。两组化疗前后ECG及cTnI、LDH1、CPK-MB均无明显变化(P>0.05)。结论:在急性淋巴细胞白血病患儿应用DNR化疗时,NT-pro BNP可用于监测其对心脏的早期影响,左卡尼汀对NT-pro BNP的改善程度较对照组明显。AIM:To explore the value of N-terminal pro-brain natriuretic peptide(NT-pro BNP) in diagnosing the myocardiopathy induced by daunorubicin(DNR)and the more effective cardiac-protection drugs by investigating the changes of the NT-pro BNP levels after administrating DNR in children with acute lymphocytic leukemia.METHODS:Twenty-two children with acute lymphocytic leukemia who treated with DNR containing vincristine,L-asparaginase,prednisone,were randomly divided into two groups.The therapy group received L-CN as the cardiac-protection drug and the control group without protecting heart drug during chemotherapy with DNR.The level of NT-pro BNP in plasma was measured by immunoassay before and after using DNR and the cardiac troponin I(cTnI) and cardiac muscle enzyme(LDH1,CPK-MB) and ECG were detected before and after chemotherapy.RESULTS:The level of NT-pro BNP in plasma was increased from(53±11) pg/mL to(162±27) pg/mL(P〈0.01) in the therapy group after chemotherapy and which in the control group was increased from(51±10) pg/mL to(194±38) pg/mL(P〈0.01).There was no significant difference in the level of NT-pro BNP before chemotherapy between two groups.The level of NT-pro BNP in plasma was lower in the therapy group than that in the control group(P〈0.05).The improving condition of the level of NT-pro BNP in the therapy group was better than that in the control group after chemotherapy.There were no significant difference in the ECG and cTnI and LDH1,CPK-MB in two groups before and after chemotherapy.CONCLUSION:NT-pro BNP can be served as a good indicator for DNR-induced myocardiopathy.Compared with control group,the improving condition of NT-pro BNP is obvious treated with levocarnitine.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.219